D. Parkin, F. Bray, and J. Ferlay, Estimating the world cancer burden: Globocan 2000, International Journal of Cancer, vol.85, issue.2, pp.153-156, 2001.
DOI : 10.1002/ijc.1440

B. Vogelstein, N. Papadopoulos, and V. Velculescu, Cancer Genome Landscapes, Science, vol.339, issue.6127, pp.1546-1558, 2013.
DOI : 10.1126/science.1235122

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749880

D. Johnson and J. Sosman, Update on the Targeted Therapy of Melanoma, Current Treatment Options in Oncology, vol.13, issue.2, pp.280-292, 2013.
DOI : 10.1007/s11864-013-0226-8

H. Davies, G. Bignell, and C. Cox, Mutations of the BRAF gene in human cancer, Nature, vol.7, issue.6892, pp.949-954, 2002.
DOI : 10.1006/geno.2000.6354

H. Arkenau, R. Kefford, and G. Long, Targeting BRAF for patients with melanoma, British Journal of Cancer, vol.365, issue.3, pp.392-398, 2011.
DOI : 10.1016/S0092-8674(04)00215-6

G. Goebel, M. Zitt, and M. Zitt, Circulating Nucleic Acids in Plasma or Serum (CNAPS) as Prognostic and Predictive Markers in Patients with Solid Neoplasias, Disease Markers, vol.21, issue.3, pp.105-120, 2005.
DOI : 10.1155/2005/218759

M. Van-der-vaart and P. Pretorius, Circulating DNA, Annals of the New York Academy of Sciences, vol.23, issue.Suppl A, pp.18-26, 2008.
DOI : 10.1196/annals.1448.022

C. Pupilli, P. Pinzani, and F. Salvianti, in the Diagnosis and Follow-Up of Differentiated Papillary Thyroid Carcinoma, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.8, pp.3359-3365, 2013.
DOI : 10.1210/jc.2013-1072

M. Daniotti, V. Vallacchi, and L. Rivoltini, Detection of mutated BRAFV600E variant in circulating DNA of stage III???IV melanoma patients, International Journal of Cancer, vol.6, issue.11, pp.2439-2444, 2007.
DOI : 10.1002/ijc.22598

M. Saint-jean, G. Quereux, and J. Nguyen, Is a Single BRAF Wild-Type Test Sufficient to Exclude Melanoma Patients from Vemurafenib Therapy?, Journal of Investigative Dermatology, vol.134, issue.5, pp.1468-1470, 2014.
DOI : 10.1038/jid.2013.378

URL : http://doi.org/10.1038/jid.2013.378

M. Denis, A. Knol, and S. Theoleyre, Efficient Detection of BRAF Mutation in Plasma of Patients after Long-term Storage of Blood in Cell-Free DNA Blood Collection Tubes, Clinical Chemistry, vol.61, issue.6, pp.886-888, 2015.
DOI : 10.1373/clinchem.2015.238352

M. Colombino, M. Capone, and A. Lissia, Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma, Journal of Clinical Oncology, vol.30, issue.20, pp.2522-2529, 2012.
DOI : 10.1200/JCO.2011.41.2452

L. Heinzerling, M. Baiter, and S. Kuhnapfel, Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations, British Journal of Cancer, vol.7, issue.11, pp.2833-2841, 2013.
DOI : 10.1038/bjc.2013.622

M. Shinozaki, O. Day, S. Kitago, and M. , Utility of Circulating B-RAF DNA Mutation in Serum for Monitoring Melanoma Patients Receiving Biochemotherapy, Clinical Cancer Research, vol.13, issue.7, pp.2068-2074, 2007.
DOI : 10.1158/1078-0432.CCR-06-2120

A. Vallee, M. Marcq, and A. Bizieux, Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients, Lung Cancer, vol.82, issue.2, pp.373-374, 2013.
DOI : 10.1016/j.lungcan.2013.08.014

M. Sanmamed, S. Fernandez-landazuri, and C. Rodriguez, Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors, Clinical Chemistry, vol.61, issue.1, pp.297-304, 2015.
DOI : 10.1373/clinchem.2014.230235

S. Couraud, F. Vaca-paniagua, and S. Villar, Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002, Clinical Cancer Research, vol.20, issue.17, pp.4613-4624, 2014.
DOI : 10.1158/1078-0432.CCR-13-3063

C. Balch, J. Gershenwald, and S. Soong, Final Version of 2009 AJCC Melanoma Staging and Classification, Journal of Clinical Oncology, vol.27, issue.36, pp.6199-6206, 2009.
DOI : 10.1200/JCO.2009.23.4799

A. Diaz-lagares, E. Alegre, and A. Arroyo, Evaluation of multiple serum markers in advanced melanoma, Tumor Biology, vol.27, issue.6, pp.1155-1161, 2011.
DOI : 10.1007/s13277-011-0218-x

M. Sanmamed, S. Fernandez-landazuri, and C. Rodriguez, Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients, Clinica Chimica Acta, vol.429, pp.168-174, 2014.
DOI : 10.1016/j.cca.2013.11.034

A. Ashida, H. Uhara, and A. Mikoshiba, Melanoma with BRAF Mutation in Circulating Cell-free DNA despite no Mutation in the Primary Lesion: A Case Report, Acta Dermato Venereologica, vol.96, issue.1, pp.128-129, 2015.
DOI : 10.2340/00015555-2194

T. Sundaresan, L. Sequist, and J. Heymach, Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses, Clinical Cancer Research, vol.22, issue.5, pp.1103-1110, 2016.
DOI : 10.1158/1078-0432.CCR-15-1031